FLT3 Inhibitors Impact Treatment Landscape for Patients With FLT3-Mutated AML
September 18th 2019Gail Roboz, MD, discusses the use of FLT3 inhibitors as treatment of patients with acute myeloid leukemia, which can be a heterogenous and difficult-to-treat disease. There is a lot of optimism for new drugs and targets in AML, but the disease itself remains tough to treat, according to Roboz.